Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism

Translational Research

Volumn 152, Issue 3, 2008, Pages 134-142

  Ma, Shuk woon ^a   Benzie, Iris F F ^a   Yeung, Vincent T F ^a  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; APOLIPOPROTEIN E; ASCORBIC ACID; BIOLOGICAL MARKER; CHOLESTEROL; CREATININE; HEMOGLOBIN A1C; LIPID; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY INJURY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; ALPHA-TOCOPHEROL; APOLIPOPROTEIN E2; ASCORBIC ACID; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HONG KONG; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 51749100072     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.07.003     Document Type: Article

References (51)

1. Cockram C.S. Diabetes mellitus: perspective from the Asia-Pacific region. Diabetes Res Clin Pract 50 (2000) S3-S7
2. Ho Y.W., Chau K.F., Leung C.B., et al. Hong Kong Registry Report 2004. Hong Kong J Nephrol 7 (2005) 38-46
3. Wu A.Y., Kong N.C., de Leon F.A., et al. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48 (2005) 17-26
4. Choy B.Y., Ho Y.W., Chau K.F., Leung C.B., Tsang W.K., and Lui S.F. Renal replacement therapy for patients with diabetes mellitus in Hong Kong. Hong Kong J Nephrol 3 (2001) 89-96
5. Tam T.K.W., Cheng L.P.K., Lau D.M.W., et al. The prevalence of microalbuminuria among patients with type II diabetes mellitus in a primary care setting: cross-sectional study. Hong Kong Med J 10 (2004) 307-311
6. Yang X.L., So W.Y., Kong A.P., et al. End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry. Diabetologia 49 (2006) 2299-2308
7. Haire-Joshu D., Glasgow R.E., and Tibbs T.L. Smoking and diabetes. Diabetes Care 22 (1999) 1887-1898
8. Marshall S.M., and Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 333 (2006) 475-480
9. Yu Y., and Lyons T.J. A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci 330 (2005) 227-232
10. Liberopoulos E., Siamopoulos K., and Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 43 (2004) 223-233
11. Vaisi-Raygani A., Rahimi Z., Nomani H., Tavilani H., and Pourmotabbed T. The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 40 (2007) 1150-1156
12. Kalix B., Meynet M.C., Garin M.C., and James R.W. The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med 18 (2001) 445-450
13. Liu L., Xiang K., Zheng T., Zhang R., Li M., and Li J. Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem 254 (2003) 353-358
14. Siest G., Bertrand P., Herbeth B., et al. Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med 38 (2000) 841-852
15. Bennet A.M., Di Angelantonio E., Ye Z., et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298 (2007) 1300-1311
16. Subbiah M.T. Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine. Transl Res 149 (2007) 55-61
17. Liberopoulos E.N., Miltiadous G.A., Cariolou M., Kalaitzidis R., Siamopoulos K.C., and Elisaf M.S. Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant 19 (2004) 2006-2012
18. Eto M., Saito M., Okada M., et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 40 (2002) 243-251
19. Ha S.K., Park H.S., Kim K.W., et al. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 14 (1999) 2144-2149
20. Hsieh M.C., Lin S.R., Yang Y.C., Chen H.C., Lin J.N., and Shin S.J. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 15 (2002) 368-373
21. Liberopoulos E.N., Miltiadous G.A., Athyros V.G., et al. Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. J Investig Med 53 (2005) 116-122
22. Dietrich M., Hu Y., Block G., et al. Associations between apolipoprotein E genotype and circulating F2-isoprostane levels in humans. Lipids 40 (2005) 329-334
23. Gottlieb M.G., Schwanke C.H., Santos A.F., Jobim P.F., Mussel D.P., and da Cruz I.B. Association among oxidized LDL levels, MnSOD, apolipoprotein E polymorphisms, and cardiovascular risk factors in a south Brazilian region population. Genet Mol Res 4 (2005) 691-703
24. Ma Y.C., Zuo L., Chen J.H., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) 2937-2944
25. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. WHO/NCD/NCS/99.2 (1999), WHO, Geneva, Switzerland
26. Benzie I.F., and Strain J.J. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol 299 (1999) 15-27
27. Chung W.Y., Chung J.K., Szeto Y.T., Tomlinson B., and Benzie I.F. Plasma ascorbic acid: measurement, stability and clinical utility revisited. Clin Biochem 34 (2001) 623-627
28. Benzie I.F., Chung W., and Tomlinson B. Simultaneous measurement of allantoin and urate in plasma: analytical evaluation and potential clinical application in oxidant:antioxidant balance studies. Clin Chem 45 (1999) 901-904
29. Thurnham D.I., Davies J.A., Crump B.J., Situnayake R.D., and Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 23 (1986) 514-520
30. Jentzsch A.M., Bachmann H., Furst P., and Biesalski H.K. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med 20 (1996) 251-256
31. Benzie I.F.F. Uric acid: friend or foe. Redox Rep 2 (1996) 231-234
32. Molitch M.E., DeFronzo R.A., Franz M.J., et al. Nephropathy in diabetes. Diabetes Care 27 (2004) S79-S83
33. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98 (1991) S823-S833
34. Ng M.C., Baum L., So W.Y., et al. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 -455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet 70 (2006) 20-28
35. Araki S., Koya D., Makiishi T., et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 26 (2003) 2416-2420
36. Eto M., Horita K., Morikawa A., et al. Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 48 (1995) 288-292
37. Horita K., Eto M., and Makino I. Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107 (1994) 203-211
38. Kimura H., Suzuki Y., Gejyo F., et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 31 (1998) 666-673
39. Parving H.H., Lewis J.B., Ravid M., Remuzzi G., and Hunsicker L.G. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69 (2006) 2057-2063
40. Boizel R., Benhamou P.Y., Corticelli P., Valenti K., Bosson J.L., and Halimi S. ApoE polymorphism and albuminuria in diabetes mellitus: a role for LDL in the development of nephropathy in NIDDM?. Nephrol Dial Transplant 13 (1998) 72-75
41. Vauhkonen I., Niskanen L., Ryynanen M., et al. Divergent association of apolipoprotein E polymorphism with vascular disease in patients with NIDDM and control subjects. Diabet Med 14 (1997) 748-756
42. Werle E., Fiehn W., and Hasslacher C. Apolipoprotein E polymorphism and renal function in German type 1 and type 2 diabetic patients. Diabetes Care 21 (1998) 994-998
43. Lehtinen S., Rantalaiho V., Wirta O., et al. Apolipoprotein E gene polymorphism, hypercholesterolemia and glomerular filtration rate in type 2 diabetic subjects: A 9-year follow-up study. J Biomed Sci 10 (2003) 260-265
44. Brouwer D.A., van Doormaal J.J., and Muskiet F.A. Clinical chemistry of common apolipoprotein E isoforms. J Chromatogr B Biomed Appl 678 (1996) 23-41
45. Wenham P.R., Sedky A., and Spooner R.J. Apolipoprotein E phenotyping: a word of caution. Ann Clin Biochem 28 (1991) 599-605
46. Leiva E., Mujica V., Elematore I., et al. Relationship between Apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract 78 (2007) 196-201
47. Joss N., Jardine A., Gaffney D., and Boulton-Jones J.M. Influence of apolipoprotein E genotype on progression of diabetic nephropathy. Nephron Exp Nephrol 101 (2005) e127-e133
48. Ilhan N., Kahraman N., Seckin D., Ilhan N., and Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct 25 (2007) 527-532
49. Hsu C.C., Kao W.H., Coresh J., et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 293 (2005) 2892-2899
50. Hsu C.C., Coresh J., and Kao W.H.L. Apolipoprotein E and progression of chronic kidney disease (response to letter by Kida, Y.). JAMA 295 (2006) 35-36
51. Freedman B.I., Bostrom M., Daeihagh P., and Bowden D.W. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2 (2007) 1306-1316